Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech submitted its Q1 FY26 (quarter ended June 30, 2025) unaudited standalone and consolidated financial results to the exchanges. Standalone revenue from operations stood at approximately ₹38.45 crore, down about 7% year-on-year from ₹41.48 crore in Q1 FY25. Standalone profit after tax came in around ₹1.64 crore versus about ₹2.26 crore in the year-ago quarter, impacted by an exceptional item of roughly ₹1.88 crore related to commercial tax expenses from earlier years. Consolidated PAT was around ₹1.60 crore, more than doubling from about ₹0.76 crore in Q1 FY25 on the back of subsidiary contributions. The board also approved the draft FY25 annual report, appointed two new independent directors (Mr. Sham Goel and Mr. Shaival Saurabh), redesignated Mr. Ashwani Kumar Sharma as Executive Director, and recommended a final dividend of ₹1 per equity share (10%) for FY25 subject to shareholder approval at the 32nd AGM scheduled for September 26, 2025. The auditors (Rai Qimat & Associates) issued a limited review report with an unmodified opinion on both standalone and consolidated results.
Mixed signals for shareholders — standalone top line and profits dipped YoY due to a one-time commercial tax hit, while consolidated earnings more than doubled. The recommended ₹1 dividend and clean auditor opinion are positives, but investors should watch whether the exceptional commercial tax charge is a recurring risk to standalone margins.